Skip to main content

Table 3 Annual rates of change in eGFR (mL/min/1.73 m2, 95% CI) for subgroups of Cohort 2

From: Effects of tolvaptan discontinuation in patients with autosomal dominant polycystic kidney disease: a post hoc pooled analysis

 

Number of subjects

On treatment

Post-treatment

Difference

Risk class 1B or 1C

1B: 10; 1C: 25

-1.02 (-1.77, -0.26)

-5.05 (-6.22, -3.88)

4.03 (2.70, 5.36), P < 0.001

Risk class 1D or 1E

1D: 31; 1E: 16

-2.66 (-3.29, -2.04)

-4.84 (-5.63, -4.05)

2.17 (1.21, 3.13), P < 0.001

Female

42

-1.59 (-2.32, -0.87)

-5.47 (-6.36, -4.58)

3.88 (2.80, 4.96), P < 0.001

Male

40

-2.22 (-2.85, -1.59)

-3.63 (-4.72, -2.53)

1.41 (0.19, 2.62), P = 0.02

  1. CI confidence interval, eGFR estimated glomerular filtration rate